register free | resend password

Pressemitteilungen zu dem Thema parexel


Unterkategorien

PresseMitteilungen zu dem Schlagwort parexel


PAREXEL and CHA Medical Group Partner to Enhance Early Phase Clinical Research in Korea

Collaboration combines best-in-class offerings from CHA and PAREXEL to enhance early phase clinical trials in growing hub for drug development BOSTON, March 13, 2018 - PAREXEL International Corporation, the world''s leading innovator of biopharmaceutical services, today announced an alliance with CHA Medical Group (CHA) to enhance early phase clinical development in Korea. The collaboration is designed to provide biopharmaceutical companies with comprehensive services that leverage PA ...


13.03.2018

PAREXEL Appoints Jamie Macdonald as Chief Executive Officer

BOSTON, March 6, 2018 - PAREXEL International Corporation, the world''s leading innovator of biopharmaceutical services, today announced the appointment of Jamie Macdonald as Chief Executive Officer (CEO) effective March 15, 2018. Josef von Rickenbach, who co-founded the Company, will retire from his daily CEO duties and continue as Chairman of the Board. "It is a tremendous honor for me to join PAREXEL," said Jamie Macdonald. "As a trail blazer in the biopharmaceutic ...


06.03.2018

PAREXEL Introduces Biological Sample Lifecycle Management Service to Address Growing Demand Across Drug Development

BOSTON, February 12, 2018 - PAREXEL International Corporation, the world''s leading innovator of biopharmaceutical services, today launched its Biological Sample Lifecycle Management service, enabling optimal use of human biological samples. The new service enables biopharmaceutical clients to more efficiently manage their often irreplaceable patient biological sample assets from informed consent and collection at site, through in-study laboratory analysis, data generation and future u ...


12.02.2018

PAREXEL Announces Enhanced Global Data Operations Offering to Drive Efficiencies for Life Science Companies

BOSTON, December 18, 2017 al programming and biostatistics. The enhanced offering is designed to help the biopharmaceutical industry reduce time to market and R&D costs for clinical trials, including complex multi-indication trials. PAREXEL is introducing features with its GDO offering including: ts can utilize adaptive trials to reduce uncertainty when planning, better inform decision making, and reduce risks for subjects and sponsors. PAREXEL and tailored to the unique needs of each tri ...


18.12.2017

PAREXEL Launches Perceptive® Cloud for the Life Sciences Industry

Cloud Platform Built on Microsoft Azure Delivers PAREXEL BOSTON, December 12, 2017 Perceptive Cloud elevates PAREXEL Informatics solutions into an enhanced cloud infrastructure built on Microsoft Azure, combining PAREXEL Perceptive Cloud is designed to respond to the need within healthcare to deliver cost-effective innovation while trusting that sensitive information will stay secure across global environments. Introducing Perceptive Cloud represents the first milestone of the enterprise al ...


12.12.2017

PAREXEL Expands Global Regulatory Services with Addition of Senior Executives from FDA and Oncology Industry

New Appointments Enhance PAREXEL’s Leadership and Expertise in Bringing Commercially Viable, Reimbursable Products to Market BOSTON, November 15, 2017 - PAREXEL, a leading global biopharmaceutical services provider, today announced the appointment of three former senior regulatory consulting executives from the U.S. Food and Drug Administration (FDA) and Oncology industry positions. The new hires are part of PAREXEL’s Global Integrated Product Development and Compliance team and will be focused ...


15.11.2017

PAREXEL Enhances Its Active Tracking Service with Bluetooth Capability to Improve Monitoring of Temperature-Controlled Medication

BOSTON, October 27, 2017 – PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced a new feature for its ClinPhone® RTSM (randomization and trial supply management) Mobile App that addresses the workflow and safety issues commonly associated with the packaging, transport, and storage of temperature-sensitive medications. The industry-first capability will provide end-to-end temperature monitoring that records the complete temperature history of a ...


27.10.2017

PAREXEL Launches Real-World Data Service Offering to Drive Value Demonstration of New Treatments

Integrated offering to be provided by new dedicated service group under PAREXEL® Access BOSTON, September 6, 2017 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has launched a new end-to-end service offering to provide real-world data insights that help life science companies more effectively demonstrate product value. “In an increasingly competitive market, leveraging data to demonstrate value is critical. How ...


06.09.2017

PAREXEL and Osaka International Cancer Institute Form Alliance to Advance Clinical Research in Japan

BOSTON and OSAKA, August 21, 2017– PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Osaka International Cancer Institute today announced that they have formed an alliance to advance clinical development in Japan. The partnership will aim to drive greater efficiencies in support of patient recruitment for clinical trials in oncology and hematology, accelerating the development of innovative and effective new cancer treatments for patients ...


21.08.2017

PAREXEL introduces its Connected Journey™ of newly integrated data-driven services to simplify drug development and commercialisation

LONDON, June 19, 2017 – As life science companies increasingly seek to gain insights from diverse data sources to make drug development more efficient and effective, PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, is launching its Connected Journey™ of data-driven services. This newly integrated network, powered by PAREXEL® Analytics capabilities, combines PAREXEL’s technology, processes, and expertise to deliver critical intelligence suppo ...


19.06.2017

PAREXEL Collaborates With Sanofi To Advance The Use Of Wearable Devices In Life Science Industry

LONDON, June 15, 2017 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation, today announced a collaboration with Sanofi to advance the use of wearable devices to transform the collection of data in clinical trials. Wearables have the potential to address several challenges related to clinical trials and improve execution by increasing patients’ ability to participate, driving patient engagement, and creating more opportunities for decentra ...


15.06.2017

PAREXEL Ranked A Top CRO In CenterWatch Global Investigative Site Relationship Survey

Company recognised for sponsor/site relationship quality LONDON, April 3, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation, today announced that it was named a top contract research organisation (CRO) in the CenterWatch 2017 Global Investigative Site Relationship Survey. The survey recognises CROs that have high-quality working relationships with investigative sites. The survey, published today in CenterWatch Monthly, polled over ...


03.04.2017

PAREXEL Launches Patient Sensor Solution To Transform Clinical Trial Data Collection

LONDON, March 30, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the launch of its patient sensor solution, a new offering that securely captures, transmits, stores, and visualises study subject data in clinical trials. PAREXEL’s offering, powered by the Perceptive MyTrials® Analytics platform, enables an end-to-end services and technology solution that facilitates the remote collection of study subject data via med ...


30.03.2017

PAREXEL International appoints Simon Harford as Senior Vice President and Chief Financial Officer

LONDON, February 28, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the appointment of Simon Harford as Senior Vice President and Chief Financial Officer effective June 1, 2017. He will serve on PAREXEL''s Business Review Committee, the Company''s senior-most leadership team, and assist in developing and implementing PAREXEL''s strategic objectives. Mr. Harford will be based at the Compa ...


02.03.2017

PAREXEL Launches ClinPhone RTSM Mobile App to Improve Supply Management and Increase Patient Safety

LONDON, February 13, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched a mobile app for the ClinPhone® RTSM (randomisation and trial supply management) service. The app is designed to enhance clinical trial supply management processes, increase patient safety, and improve the chain of custody record for clinical supplies. Using built-in barcode scanning capabilities, clinical trial site staff, including principal inves ...


13.02.2017

PAREXEL Announces Definitive Agreement to Acquire The Medical Affairs Company

Acquisition will strengthen and add scale to current commercialisation and medical affairs services LONDON, February 2, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has entered into a definitive agreement to acquire The Medical Affairs Company, LLC (“TMAC”), a leading provider of outsourced medical affairs services to the pharmaceutical, biotechnology, and medical device industries. The acquisitio ...


02.02.2017

PAREXEL Expands Managed Access Programs Service Offering

Simplified, end-to-end solution will help biopharmaceutical clients provide compassionate access to their treatments for patients London, January 26, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched an expanded Managed Access Programs service. PAREXEL now offers end-to-end expertise for the design, development, and delivery of managed access programs to help biopharmaceutical companies provide access to investigational ...


26.01.2017

PAREXEL Launches IDMP-Focused Software And Service Solution

Solution developed to help biopharmaceutical companies meet emerging regulatory requirements ahead of deadline LONDON, November 14, 2016 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched an Identification of Medicinal Products (IDMP)-focused solution for biopharmaceutical companies. LIQUENT InSight® for IDMP™ is the newest module added to PAREXEL’s Regulatory Information Management (RIM) platform. Beginning in 2018, the Eu ...


14.11.2016

PAREXEL Launches Active Tracking Service For Monitoring And Managing Temperature-Controlled Investigational Medicinal Products

BOSTON, October 6, 2016 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced the launch of its Active Tracking service. The service follows Good Distribution Practice (GDP) requirements by providing biopharmaceutical companies with near real-time temperature and location monitoring of investigational medicinal products (IMPs) from central distribution centers to clinical trial sites. An increasing number of medicinal produ ...


06.10.2016

PAREXEL Announces Execution Of Definitive Agreement To Acquire ExecuPharm

Acquisition will strengthen and add scale to current functional services offering to meet growing demand London, UK: September 26, 2016 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has entered into a definitive agreement to acquire ExecuPharm, Inc. (“ExecuPharm”), a leading, global functional service provider (FSP) serving the biopharmaceutical industry. The acquisition is expected to close in the next ...


26.09.2016

PAREXEL Appoints Four Executives to Senior Leadership Team

BOSTON, August 1, 2016 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the appointment of four company executives to its senior-most leadership team, the Business Review Committee: • David Godwin, Senior Vice President, Global Business Development • Michelle Graham, Senior Vice President and Chief Human Resources Officer • Sy Pretorius, M.D., Senior Vice President and Chief Scientific Officer • ...


01.08.2016

PAREXEL And EMC Form Alliance To Provide Cloud-Based Document And Regulatory Information Management Services

LONDON, 13th April, 2016 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation, and EMC Corporation (NYSE: EMC) today announced they have entered into an alliance to offer an end-to-end Regulatory Information Management (RIM) and Regulatory Content Management solution. By combining PAREXEL® LIQUENT InSight® Regulatory Information Management platform and EMC® Documentum® for Life Sciences software solution suite, PAREXEL now provides life sc ...


13.04.2016



All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 70


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.